Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals (REGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 81,122,760
  • Shares Outstanding, K 105,099
  • Annual Sales, $ 14,202 M
  • Annual Income, $ 4,413 M
  • EBIT $ 3,688 M
  • EBITDA $ 4,171 M
  • 60-Month Beta 0.37
  • Price/Sales 5.73
  • Price/Cash Flow 16.93
  • Price/Book 2.63

Options Overview Details

View History
  • Implied Volatility 38.17% (+0.57%)
  • Historical Volatility 33.23%
  • IV Percentile 56%
  • IV Rank 35.36%
  • IV High 60.01% on 04/08/25
  • IV Low 26.22% on 11/26/25
  • Expected Move (DTE 7) 20.40 (2.64%)
  • Put/Call Vol Ratio 1.86
  • Today's Volume 2,375
  • Volume Avg (30-Day) 2,093
  • Put/Call OI Ratio 0.50
  • Today's Open Interest 51,596
  • Open Int (30-Day) 55,292
  • Expected Range 751.47 to 792.27

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 27 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 8.06
  • Number of Estimates 6
  • High Estimate 10.82
  • Low Estimate 6.92
  • Prior Year 9.90
  • Growth Rate Est. (year over year) -18.59%

Price Performance

See More
Period Period Low Period High Performance
1-Month
691.86 +11.56%
on 12/09/25
792.77 -2.64%
on 12/24/25
-8.32 (-1.07%)
since 11/28/25
3-Month
541.00 +42.67%
on 10/13/25
792.77 -2.64%
on 12/24/25
+209.60 (+37.28%)
since 09/30/25
52-Week
476.49 +61.99%
on 06/05/25
792.77 -2.64%
on 12/24/25
+69.28 (+9.86%)
since 12/30/24

Most Recent Stories

More News
3 Reasons to Avoid REGN and 1 Stock to Buy Instead

3 Reasons to Avoid REGN and 1 Stock to Buy Instead

REGN : 771.87 (-0.27%)
Stocks Fall Slightly in Thin Holiday Trade

The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed down -0.14%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.20%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.25%. March E-mini...

C : 116.69 (-0.44%)
RARE : 23.00 (+0.97%)
HL : 19.19 (-1.54%)
SLB : 38.38 (-0.44%)
$IUXX : 25,249.85 (unch)
ZNH26 : 112-110 (-0.08%)
OXY : 41.12 (-0.82%)
ESH26 : 6,927.75 (+0.51%)
FANG : 150.33 (-0.61%)
JBL : 228.02 (-1.53%)
$DOWI : 48,063.29 (-0.63%)
SPY : 681.92 (-0.74%)
Stocks Slip as Bond Yields Rise

The S&P 500 Index ($SPX ) (SPY ) today is down -0.12%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.25%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.11%. March E-mini S&P futures...

C : 116.69 (-0.44%)
RARE : 23.00 (+0.97%)
SLB : 38.38 (-0.44%)
$IUXX : 25,249.85 (unch)
ZNH26 : 112-110 (-0.08%)
OXY : 41.12 (-0.82%)
ESH26 : 6,927.75 (+0.51%)
FANG : 150.33 (-0.61%)
$DOWI : 48,063.29 (-0.63%)
SPY : 681.92 (-0.74%)
DIA : 480.57 (-0.62%)
INSM : 174.04 (-0.03%)
3 Cash-Heavy Stocks We Approach with Caution

3 Cash-Heavy Stocks We Approach with Caution

FBNC : 50.79 (-1.32%)
BK : 116.09 (-0.67%)
REGN : 771.87 (-0.27%)
Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma

Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function (by 4.68% to 5.32%) compared to placebo Dupixent...

SAN.FP : 82.090 (-0.76%)
REGN : 771.87 (-0.27%)
SNY : 48.46 (-0.57%)
Regeneron Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference

TARRYTOWN, N.Y., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:  REGN ) will webcast its presentation at the 44 th Annual J.P. Morgan Healthcare Conference on Monday, January...

REGN : 771.87 (-0.27%)
Pfizer Adds to Its Big Bet on Weight Loss Drugs

A month after acquiring obesity biotech Metsera, Pfizer's expanding in the weight loss drug market after signing a licensing agreement for a weight loss pill.

NVO : 50.88 (-0.66%)
JNJ : 206.95 (+0.02%)
LLY : 1,074.68 (-0.47%)
REGN : 771.87 (-0.27%)
PFE : 24.90 (-0.36%)
2 Large-Cap Stocks on Our Buy List and 1 We Find Risky

2 Large-Cap Stocks on Our Buy List and 1 We Find Risky

NOW : 153.19 (-0.67%)
PGR : 227.72 (-0.98%)
REGN : 771.87 (-0.27%)
3 Low-Volatility Stocks We’re Skeptical Of

3 Low-Volatility Stocks We’re Skeptical Of

CMCSA : 29.89 (-0.27%)
REGN : 771.87 (-0.27%)
KFY : 66.02 (-1.27%)
Lynozyficâ„¢ (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment

All three dose groups (50 mg, 100 mg and 200 mg) showed impressive monotherapy efficacy, with VGPR+ (very good partial response or better) of ≥70% despite limited follow-up; evidence shows that these...

REGN : 771.87 (-0.27%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Regeneron is a biotechnology company focused on the discovery, development and commercialization of treatments targeting serious medical conditions. The company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. The company also...

See More

Key Turning Points

3rd Resistance Point 780.69
2nd Resistance Point 777.84
1st Resistance Point 774.86
Last Price 771.87
1st Support Level 769.03
2nd Support Level 766.18
3rd Support Level 763.20

See More

52-Week High 792.77
Last Price 771.87
Fibonacci 61.8% 671.95
Fibonacci 50% 634.63
Fibonacci 38.2% 597.31
52-Week Low 476.49

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar